Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer.
Cancer Invest
; 27(10): 984-8, 2009 Dec.
Article
em En
| MEDLINE
| ID: mdl-19909013
ABSTRACT
PURPOSE:
To evaluate the incidence of skeletal complications in patients with multiple myeloma, and metastatic breast, prostate, or lung cancers, when therapy with intravenous bisphosphonates is continued for longer than 21 months.METHODS:
The primary outcome was the diagnosis of at least one skeletal-related event (SRE) after 21 months of therapy. The secondary outcome was the incidence of osteonecrosis of the jaws (ONJ).RESULTS:
The primary outcome was 30%. The secondary outcome was 3%, while six patients (5%) were referred to a dentist for suspected ONJ.CONCLUSION:
There appears to be a continued benefit when intravenous bisphosphonates are given for longer than 21 months.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Compressão da Medula Espinal
/
Neoplasias Ósseas
/
Difosfonatos
/
Fraturas Ósseas
/
Conservadores da Densidade Óssea
/
Imidazóis
Tipo de estudo:
Etiology_studies
/
Observational_studies
/
Risk_factors_studies
Limite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2009
Tipo de documento:
Article